Pharma BD Deal Intelligence
F. Hoffmann-La Roche AG / MediLink Therapeutics (Suzhou) Co., Ltd.
2026 · Licensing/Option · $570M · Complete
MediLink Therapeutics signed an additional exclusive licensing agreement with Roche for YL201, a B7-H3-targeting antibody-drug conjugate for solid tumors. Trade press reported approximately USD 570M in near-term payments to MediLink. This is a second agreement between the two companies, following an earlier MediLink-Roche ADC license.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.
Key facts
- Announced Jan 08, 2026
- Deal value $570M
- Deal type Licensing/Option
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2026 deals · F. Hoffmann-La Roche AG deals